BRISBANE, Calif., Feb. 3, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that President and Chief Executive Officer Hoyoung Huh, M.D., Ph.D., will present information on BiPar’s development programs and product pipeline, including the latest information on the company’s lead product candidate, BSI-201 which is in randomized Phase 2 clinical trials in triple negative breast cancer, at the 2009 BIO CEO & Investor Conference 2009 located in New York City, NY.
